Literature DB >> 8400604

Reduced bone formation in patients with osteoporosis associated with inflammatory bowel disease.

P I Croucher1, S Vedi, R J Motley, N J Garrahan, M R Stanton, J E Compston.   

Abstract

The pathophysiology of bone loss associated with inflammatory bowel disease has not been clearly defined. In this study we have performed a detailed histomorphometric analysis of iliac crest bone obtained from 19 patients with inflammatory bowel disease in whom a diagnosis of osteoporosis had been made. Eleven subjects were receiving prednisolone at the time of their biopsy. Comparison with control values demonstrated a highly significant reduction in trabecular bone area in the patient group (p < 0.001). Wall width, adjusted appositional rate and bone formation rate were all significantly reduced in the patient group (p < 0.001) and the formation period was significantly increased (p < 0.001). Resorption cavities were slightly smaller in the patient group, differences in maximum cavity depth and cavity length achieving statistical significance (p < 0.005 and p < 0.05 respectively). The mineral appositional rate was significantly reduced in the patients with inflammatory bowel disease (p < 0.001) and the mineralization lag time significantly increased (p < 0.001); however, osteoid area, perimeter and seam width were not significantly different from controls. These results demonstrate that osteoporosis associated with inflammatory bowel disease is characterized by reduced bone formation at the cellular and tissue level; the proportionately greater change in wall width than in resorption cavity depth is consistent with a negative remodelling balance. Although none of the patients had osteomalacia as defined by the criteria of increased osteoid seam width and mineralization lag time, the higher mineralization lag time in the patient group indicates a mild mineralization defect.

Entities:  

Mesh:

Year:  1993        PMID: 8400604     DOI: 10.1007/bf01623826

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  21 in total

1.  Osteomalacia in sprue.

Authors:  H A SALVESEN; J BOE
Journal:  Acta Med Scand       Date:  1953

2.  A computerised technique for the quantitative assessment of resorption cavities in trabecular bone.

Authors:  N J Garrahan; P I Croucher; J E Compston
Journal:  Bone       Date:  1990       Impact factor: 4.398

3.  Bone histomorphometry and structure in corticosteroid treated chronic active hepatitis.

Authors:  A J Stellon; A Webb; J E Compston
Journal:  Gut       Date:  1988-03       Impact factor: 23.059

4.  Effect of chronic corticosteroid administration on diaphyseal and metaphyseal bone mass.

Authors:  T J Hahn; V C Boisseau; L V Avioli
Journal:  J Clin Endocrinol Metab       Date:  1974-08       Impact factor: 5.958

5.  Increased rate of spinal trabecular bone loss in patients with inflammatory bowel disease.

Authors:  R J Motley; E O Crawley; C Evans; J Rhodes; J E Compston
Journal:  Gut       Date:  1988-10       Impact factor: 23.059

6.  Osteopenia with normal vitamin D metabolites after small-bowel resection for Crohn's disease.

Authors:  I Hessov; L Mosekilde; F Melsen; S Fasth; L Hultén; B Lund; B Lund; O H Sørensen
Journal:  Scand J Gastroenterol       Date:  1984-07       Impact factor: 2.423

7.  Calcium balance and bone mineral content following small-intestinal resection.

Authors:  E Hylander; K Ladefoged; S Madsen
Journal:  Scand J Gastroenterol       Date:  1981       Impact factor: 2.423

8.  Vitamin D prophylaxis and osteomalacia in chronic cholestatic liver disease.

Authors:  J E Compston; J P Crowe; I P Wells; L W Horton; D Hirst; A L Merrett; J S Woodhead; R Williams
Journal:  Dig Dis Sci       Date:  1980-01       Impact factor: 3.199

9.  Plasma levels and intestinal absorption of 25-hydroxyvitamin D in patients with small bowel resection.

Authors:  J E Compston; B Creamer
Journal:  Gut       Date:  1977-03       Impact factor: 23.059

View more
  12 in total

Review 1.  Bone abnormalities in gastrointestinal and hepatic disease.

Authors:  F A Sylvester
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

Review 2.  Nitric oxide and bone.

Authors:  R J van't Hof; S H Ralston
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

3.  Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density.

Authors:  M T Abreu; V Kantorovich; E A Vasiliauskas; U Gruntmanis; R Matuk; K Daigle; S Chen; D Zehnder; Y-C Lin; H Yang; M Hewison; J S Adams
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

4.  Mutifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn's disease.

Authors:  Sarah A Bartram; Robert T Peaston; David J Rawlings; David Walshaw; Roger M Francis; Nick P Thompson
Journal:  World J Gastroenterol       Date:  2006-09-21       Impact factor: 5.742

5.  Fracture risk is increased in Crohn's disease, but not in ulcerative colitis.

Authors:  P Vestergaard; K Krogh; L Rejnmark; S Laurberg; L Mosekilde
Journal:  Gut       Date:  2000-02       Impact factor: 23.059

6.  Metabolic Bone Disease in Inflammatory Bowel Disease.

Authors:  Alan L. Buchman
Journal:  Curr Treat Options Gastroenterol       Date:  2002-06

7.  Inflammatory bowel disease and predisposition to osteopenia.

Authors:  F J Cowan; J T Warner; F D Dunstan; W D Evans; J W Gregory; H R Jenkins
Journal:  Arch Dis Child       Date:  1997-04       Impact factor: 3.791

Review 8.  Corticosteroid-induced bone loss. Prevention and management.

Authors:  C Picado; M Luengo
Journal:  Drug Saf       Date:  1996-11       Impact factor: 5.606

9.  Iliac bone histomorphometry in children with newly diagnosed inflammatory bowel disease.

Authors:  L M Ward; F Rauch; M A Matzinger; E I Benchimol; M Boland; D R Mack
Journal:  Osteoporos Int       Date:  2009-06-06       Impact factor: 4.507

10.  Bone loss in patients with inflammatory bowel disease: a prospective study.

Authors:  C Roux; V Abitbol; S Chaussade; S Kolta; S Guillemant; M Dougados; B Amor; D Couturier
Journal:  Osteoporos Int       Date:  1995-05       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.